Ann Arbor, Michigan 48109

  • Post Partum Depression


This study will test a consumer health light therapy device (Re-Timer) for women with postpartum depression to better understand how it affects mood and the body clock (also called the circadian clock). Eligible participants will be enrolled and randomized after baseline assessments. In addition to using the Re-Timer light for 5 weeks participants will complete questionnaires at various timepoints, record sleep information, wear an actigraph watch, and provide saliva samples. Additionally, the sleep of the participants' infants will also be monitored using an ankle-worn device (actigraph) and sleep diary at certain time-points as this may influence the mother's mood/sleep, and in turn affect the results. The hypotheses regarding the bright light versus the placebo dim light of the study are: - morning bright light therapy will produce greater improvement from pre- to post-treatment on the Hamilton Rating Scale for Depression - morning bright light therapy will lengthen the Phase angle difference (PAD) and this will mediate change in depression symptoms. - morning bright light therapy will produce greater improvements on self-reported depression symptoms, excessive daytime sleepiness, maternal-infant bonding, social functioning, and sleep-related impairment from pre- to post-treatment.


Inclusion Criteria: - less or equal (≤) to 24 weeks postpartum - meet criteria for current major depressive disorder per the Structured Clinical Interview for Diagnostic (SCID) and Statistical Manual of Mental Disorders version 5 (DSM-V) - not currently receiving treatment for depression (for example, prescription medications or psychotherapy). Exclusion Criteria: - Current diagnosis of Posttraumatic stress disorder (PTSD), obsessive compulsive disorder, eating disorder, substance abuse or dependence, lifetime history of mania/hypomania or thought disorder per SCID. - current diagnosis of, or high risk for, sleep-disordered breathing, insomnia disorder, restless leg syndrome, and/or narcolepsy. - retinal pathology or history of eye surgery - current use of photosensitizing medications, - current use of exogenous melatonin or medications that may interfere with the measurement of melatonin (nonsteroidal anti-inflammatory drugs (NSAIDs) if used daily, and beta-blockers) - medical conditions for which bright light therapy is contraindicated (for example, epilepsy/seizures).



Primary Contact:

Principal Investigator
Leslie Swanson, Ph.D.
University of Michigan

Kelley DuBuc
Phone: 734-764-2256

Backup Contact:


Location Contact:

Ann Arbor, Michigan 48109
United States

Kelley DuBuc
Phone: 734-764-2256

Site Status: Recruiting

Data Source:

Date Processed: July 01, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.